PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4687-4696

  Ghosh, Arnab ^a   Holland, Amanda M ^a   Dogan, Yildirim ^a   Yim, Nury L ^a   Rao, Uttam K ^a   Young, Lauren F ^a   West, Mallory L ^a   Singer, Natalie V ^a   Lee, Hae ^a   Na, Il Kang ^b   Tsai, Jennifer J ^a   Jenq, Robert R ^a   Penack, Olaf ^b   Hanash, Alan M ^a   Lezcano, Cecilia ^d   Murphy, George F ^d   Liu, Chen ^e   Sadelain, Michel ^a   Sauer, Martin G ^c   Sant'Angelo, Derek ^f   Van Den Brink, Marcel R M ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROMYELOCYTIC LEUKEMIA ZINC FINGER; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; LYMPHOCYTE TRANSFER; MIXED LYMPHOCYTE REACTION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEADY STATE; SURVIVAL RATE; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84881423119     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4699     Document Type: Article

References (28)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091-101.
2. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010;10:213-21.
3. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009;114: 3101-12.
4. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, et al. IL- 17 contributes to CD4-mediated graft-versus-host disease. Blood 2009;113:945-52.
5. Hanash AM, Kappel LW, Yim NL, Nejat RA, Goldberg GL, Smith OM, et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011;118:446-55.
6. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, et al. T helper17 cells are sufficient but not necessary to induce acute graftversus- host disease. Biol Blood Marrow Transplant 2010;16: 170-8.
7. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 2008;9:1055-64.
8. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008;29:391-403.
9. Raberger J, Schebesta A, Sakaguchi S, Boucheron N, Blomberg KE, Berglof A, et al. The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells. Proc Natl Acad Sci U S A 2008;105:17919-24.
10. Kovalovsky D, Alonzo ES, Uche OU, Eidson M, Nichols KE, Sant'Angelo DB. PLZF induces the spontaneous acquisition of memory/ effector functions in T cells independently of NKT cell-related signals. J Immunol 2010;184:6746-55.
11. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005;106:3322-30.
12. Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM, Terwey TH, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 2006;107:1703-11.
13. Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, et al. STAT-3 and ERK 1/2 phosphorylation are critical for Tcell alloactivation and graft-versus-host disease. Blood 2008;112: 5254-8.
14. Lu SX, Holland AM, Na IK, Terwey TH, Alpdogan O, Bautista JL, et al. Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease. J Immunol 2010;185:1912-9.
15. Ghosh A, Wolenski M, Klein C, Welte K, Blazar BR, Sauer MG. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion. J Immunother 2008;31:121-31.
16. Ghosh A, Koestner W, Hapke M, Schlaphoff V, Langer F, Baumann R, et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. Blood 2009;113:4440-8.
17. Thornton P, McColl BW,Cooper L, Rothwell NJ, Allan SM. Interleukin-1 drives cerebrovascular inflammation via MAP kinase-independent pathways. Curr Neurovasc Res 2010;7:330-40.
18. Eidson M, Wahlstrom J, Beaulieu AM, Zaidi B, Carsons SE, Crow PK, et al. Altered development of NKT cells, gammadelta T cells, CD8 T cells and NK cells in a PLZF deficient patient. PLoS One 2011;6: e24441.
19. Savage AK, Constantinides MG, Bendelac A. Promyelocytic leukemia zinc finger turns on the effector T cell program without requirement for agonist TCR signaling. J Immunol 2011;186:5801-6.
20. Juchem KW, Anderson BE, Zhang C, McNiff JM, Demetris AJ, Farber DL, et al. A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood 2011;118:6209-19.
21. Leveson-Gower DB, Olson JA, Sega EI, Luong RH, Baker J, Zeiser R, et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood 2011;117:3220-9.
22. Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, et al.Graft invariant natural killer T-cell dose predicts risk of acute graftversus- host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012;119:5030-6.
23. Thomas SY, Scanlon ST, Griewank KG, Constantinides MG, Savage AK, Barr KA, et al. PLZF induces an intravascular surveillance program mediated by long-lived LFA-1-ICAM-1 interactions. J Exp Med 2011; 208:1179-88.
24. Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORgammat in mice. Blood 2011;118:5011-20.
25. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-5.
26. van Den Brink MR, Moore E, Horndasch KJ, Crawford JM, Hoffman J, Murphy GF, et al. Fas-deficient lpr mice are more susceptible to graftversus- host disease. J Immunol 2000;164:469-80.
27. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
28. Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, et al. Absence of Stat1 in donor CD4 T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest 2011;121: 2554-69.